Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA OKs Tysabri relaunch
The approval covers the reintroduction of Tysabri (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the
The approval covers the reintroduction of Tysabri (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the
This agreement further strengthens the collaboration between the companies that began with the development and commercialization agreement for PTH1-34 nasal spray that was announced in February. Under terms
The offer will be GBP10.50 ($19.53) in cash for each NeuTec Share, which values the existing issued share capital of NeuTec at approximately GBP305.1 million ($568 million). The
The randomized, 120-patient study compared the combinations of Avastin (bevacizumab) plus Tarceva (erlotinib), and Avastin plus chemotherapy, to chemotherapy alone in patients with recurrent or refractory non-small cell
Computational drug design company Locus has successfully applied its novel technology in six external collaborations to date, which have demonstrated significant advantages in terms of novelty, cost and
The phase IIb clinical trial is an outpatient, multi-center, randomized, double-blind, single-dose, placebo-controlled study in approximately 400 migraine patients with or without aura. Four doses will be evaluated
The data, presented at the 2006 American Society of Clinical Oncology (ASCO) annual meeting, add to the growing body of evidence supporting the vaccine’s ability to provide strong
Under the terms of the agreement, the two companies will jointly evaluate and develop a pool of Emergent BioSolution’s proprietary antigens as the basis of a multivalent subunit
The goal of the study is to more fully define the safety and efficacy of the AIR insulin system in patients with type 1 diabetes. This study is
The single-arm, non-randomized study included 74 patients with advanced disease who had previously failed a median of three systemic therapies. Patients were given 400mg of the HDAC inhibitor